Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-22-078087)

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware

Accession Number:: 0001193125-22-078087
Form Type:: 13G Filing
Publication Date:: 2022-03-16 20:00:00

Filed By:: Frazier Life Sciences Public Fund, L.p.
Company:: Gracell Biotechnologies Inc.
Filing Date:: 2022-03-17
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Frazier Life Sciences Public Fund	17,104,865	17,104,865	17,104,865	5.1%
FHMLSP	17,104,865	17,104,865	17,104,865	5.1%
FHMLSP	17,104,865	17,104,865	17,104,865	5.1%
James N. Topper	17,104,865	17,104,865	17,104,865	5.1%
Patrick J. Heron	17,104,865	17,104,865	17,104,865	5.1%
Albert Cha	17,104,865	17,104,865	17,104,865	5.1%
James Brush	17,104,865	17,104,865	17,104,865	5.1%

Filing

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. ___)*

Gracell Biotechnologies Inc.

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

38406L 103**

(CUSIP Number)

March 10, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

**	CUSIP number 38406L 103 has been assigned to the American depositary shares (ADSs) of the issuer, which are quoted on The Nasdaq Global Select Market under the symbol GRCL. Each ADS represents five Ordinary Shares of the issuer. No CUSIP has been assigned to the Issuers Ordinary Shares.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 38406L 103

(1)

Consists of 17,104,865Ordinary Shares represented by 3,420,973 ADSs held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)	Based on 337,496,901 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuers Form 6-K as filed with the SEC on November 16, 2021.

CUSIP No. 38406L 103

(1)

(2)	Based on 337,496,901 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuers Form 6-K as filed with the SEC on November 16, 2021.

CUSIP No. 38406L 103

(1)

(2)	Based on 337,496,901 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuers Form 6-K as filed with the SEC on November 16, 2021.

CUSIP No. 38406L 103

(1)

(2)	Based on 337,496,901 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuers Form 6-K as filed with the SEC on November 16, 2021.

CUSIP No. 38406L 103

(1)

(2)	Based on 337,496,901 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuers Form 6-K as filed with the SEC on November 16, 2021.

CUSIP No. 38406L 103

(1)

(2)	Based on 337,496,901 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuers Form 6-K as filed with the SEC on November 16, 2021.

CUSIP No. 38406L 103

(1)

(2)	Based on 337,496,901 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuers Form 6-K as filed with the SEC on November 16, 2021.


Item 1(a).		Name of Issuer: Gracell Biotechnologies Inc.

Item 1(b).		Address of Issuers Principal Executive Offices: Building 12, Block B, Phase II, Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park, 215123, Peoples Republic of China

Item 2(a).		Name of Person Filing: The entities and persons filing this statement (collectively, the Reporting Persons) are: Frazier Life Sciences Public Fund, L.P. (FLSPF) FHMLSP, L.P. FHMLSP, L.L.C. James N. Topper (Topper) Patrick J. Heron (Heron) Albert Cha (Cha) James Brush (Brush and together with Topper, Heron and Cha, the Members)

Item 2(b).		Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is: c/o Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, Washington 98101


Item 2(c).	Citizenship:

	Entities:	FLSPF	- Delaware, U.S.A.
		FHMLSP, L.P.	- Delaware, U.S.A.
		FHMLSP, L.L.C.	- Delaware, U.S.A.

	Individuals:	Topper	- United States Citizen
		Heron	- United States Citizen
		Cha	- United States Citizen
		Brush	- United States Citizen


Item 2(d).		Title of Class of Securities: Ordinary Shares

Item 2(e).		CUSIP Number: 38406L 103. This CUSIP number applies to the ADSs, each representing five Ordinary Shares of the Issuer.

Item 3.		If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)		☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)		☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)		☐ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)		☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)		☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)		☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)		☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


(i)		☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)		☐ A non-U.S. institution in accordance with §240.13d1(b)(1)(ii)(J);

(k)		☐ Group, in accordance with §240.13d1(b)(1)(ii)(K).

		If filing as a non-U.S. institution in accordance with §240.13d1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: March 16, 2022	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By:	FHMLSP, L.P., its General Partner
	By:	FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: March 16, 2022	FHMLSP, L.P.
	By:	FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: March 16, 2022	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: March 16, 2022	By:	*
		James N. Topper

Date: March 16, 2022	By:	*
		Patrick J. Heron

Date: March 16, 2022	By:	**
		Albert Cha

Date: March 16, 2022	By:	**
		James Brush

Date: March 16, 2022	*By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

Exhibit Index

Exhibit

A - Agreement regarding filing of joint Schedule 13G.